Mega-cap Tech Leads a Packed Week
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Today brings one of the heaviest earnings days of the season. Microsoft, Alphabet, and Chipotle Mexican Grill all report after the close. GE Vernova and Vertiv Holdings posted numbers this morning. ADP, Garmin, Boston Scientific, and Aon also reported today.
In Europe, Mercedes-Benz Group reports today as well. Dutch car registration data, which leads its revenue by 26 days, is running 6% below the same quarter last year. That reading is fully in for Q3 and may colour the print.
Tomorrow, Wednesday 29 October, brings Amazon, Starbucks, Gilead Sciences, and Illumina after the bell. Volkswagen and Renault both report in Europe. Austrian car registrations, a moderate-fit leading indicator for Volkswagen revenue, are running 6% below last year.
Thursday brings Regeneron. Apple reports Monday 2 November, followed by Amgen and Booking Holdings on Tuesday.
No IPOs are scheduled in the next seven days. The Russell 2000 rank date falls on Thursday 30 October, with 102 names still in play. Twist Bioscience sits 1.7% below the Russell 1000 entry line, with ORTEX forecasting a 55% chance it crosses up, which would trigger an estimated $529 million of forced buying.
Stocks in this article
- MSFTMSFT data on ORTEX
- GOOGLGOOGL data on ORTEX
- CMGCMG data on ORTEX
- GEVGEV data on ORTEX
- VRTVRT data on ORTEX
- ADPADP data on ORTEX
- GRMNGRMN data on ORTEX
- BSXBSX data on ORTEX
- AONAON data on ORTEX
- AMZNAMZN data on ORTEX
- SBUXSBUX data on ORTEX
- GILDGILD data on ORTEX
- ILMNILMN data on ORTEX
- RNORNO data on ORTEX
- REGNREGN data on ORTEX
- AAPLAAPL data on ORTEX
- AMGNAMGN data on ORTEX
- BKNGBKNG data on ORTEX
- TWSTTWST data on ORTEX
How this article was generated
- Generated
- 28 Oct 2026, 16:32
- Prompt version
- v1.0
- Data sources
- EarningsAlt DataIndex Rebalance
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.